Treatment of Depression in Patients under Breast Cancer Therapy: Antidepressant-Tamoxifen Drug InteractionsCarlos Clayton Torres Aguiar*, João Vicente Augusto Aguiar and Marcelo Gondim Rocha
University of Fortaleza (UNIFOR), Fortaleza, Ceará, Brazil
- *Corresponding Author:
- Carlos Clayton Torres Aguiar
Professor in the Medicine Course
University of Fortaleza (UNIFOR)
Fortaleza, Ceará, Brazil
Tel: (85) 34773676
E-mail: [email protected]
Received date: April 22, 2017; Accepted date: May 10, 2017; Published date: May 17, 2017
Citation: Aguiar CCT, Aguiar JVA, Rocha MG (2017) Treatment of Depression in Patients under Breast Cancer Therapy: Antidepressant- Tamoxifen Drug Interactions. J Drug Metab Toxicol 8:228. doi: 10.4172/2157-7609.1000228
Copyright: © 2017 Aguiar CCT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The hormone therapy with tamoxifen is used in patients with breast cancer. The tamoxifen mechanism of action is based on the antagonist action of selective estrogen receptors. Depression and anxiety are psychiatric disorders which frequently coexist in patients with breast cancer. In the last decades, there has been an increase in the use of antidepressants. This literature review aims to provide a general view of pharmacokinetic knowledge of drug interactions between tamoxifen and antidepressants. Since tamoxifen is metabolized by CYP2D6, the use of antidepressants that are inhibitors of this is enzyme, such as paroxetine, fluoxetine and bupropion must be avoided. Based on cytochrome p450 drug interactions, it can be concluded that the use of citalopram, escitalopram, desvenlafaxine and venlafaxine are safe and effective treatment unlikely to alter tamoxifen efficacy.